Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
957.76
+5.36 (0.56%)
At close: Nov 17, 2026, 4:00 PM EST
965.00
+7.24 (0.76%)
After-hours: Nov 17, 2026, 6:14 PM EST

Regeneron Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
3,6593,1182,4882,7303,1062,886
Short-Term Investments
5,6425,4876,5248,1154,6362,809
Cash & Short-Term Investments
9,3018,6059,01310,8457,7425,695
Cash Growth
10.16%-4.52%-16.90%40.07%35.96%58.76%
Accounts Receivable
7,2065,3565,8445,2995,0235,059
Other Receivables
372.2384.9367.8368.5305.6977.5
Receivables
7,5795,7416,2125,6675,3296,037
Inventory
2,8953,2013,0872,5812,4021,951
Prepaid Expenses
1,008469.2348.4386.6411.2332.4
Restricted Cash
12.55.60.8---
Total Current Assets
20,79518,02218,66119,47915,88414,015
Property, Plant & Equipment
5,7285,3664,8174,2243,8343,482
Long-Term Investments
10,37210,5959,0605,4716,6406,878
Other Intangible Assets
1,3161,2571,1491,039915.56.7
Long-Term Deferred Tax Assets
4,5364,0773,3142,5751,724876.9
Other Long-Term Assets
1,6601,241758.8291.8216.9176.1
Total Assets
44,40540,55937,75933,08029,21525,435

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
1,140939789.5606.6589.2564
Accrued Expenses
3,5922,4872,2842,3272,0541,593
Current Portion of Leases
72037.830.31912.4719.7
Current Income Taxes Payable
-351.3213.211.7-326.3
Current Unearned Revenue
749.8553627.7458.9485.3442
Other Current Liabilities
-----287.4
Total Current Liabilities
6,2024,3683,9443,4233,1413,933
Long-Term Debt
1,9871,9861,9841,9831,9811,980
Long-Term Leases
-949924.1788.7775.8-
Long-Term Unearned Revenue
220.2208.7185.7126.769.873.3
Other Long-Term Liabilities
2,4971,7901,367785.4582.2680.2
Total Liabilities
10,9079,3028,4067,1076,5516,666

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
0.10.10.10.10.10.1
Additional Paid-In Capital
15,17313,99512,85611,3549,9498,088
Retained Earnings
39,47235,79731,67327,26023,30718,968
Treasury Stock
-20,949-18,613-15,167-12,560-10,353-8,261
Comprehensive Income & Other
-197.577.5-7.9-80.9-238.8-26.2
Shareholders' Equity
33,49931,25729,35425,97322,66418,769
Total Liabilities & Equity
44,40540,55937,75933,08029,21525,435

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
2,7072,9732,9392,7912,7702,700
Net Cash (Debt)
16,15215,89314,97413,45111,5659,833
Net Cash Growth
0.80%6.14%11.32%16.31%17.61%144.18%
Net Cash Per Share
151.44146.35130.09118.30101.8987.64
Filing Date Shares Outstanding
100.35102.62106.82107.46106.73106.44
Total Common Shares Outstanding
100.32102.6107.1107.12107106.57
Working Capital
14,59313,65414,71716,05612,74310,082
Book Value Per Share
333.93304.65274.08242.47211.81176.11
Tangible Book Value
32,18330,00028,20524,93521,74918,762
Tangible Book Value Per Share
320.81292.39263.35232.78203.26176.05
Land
-278.8288.2283.1264.5248
Buildings
-3,1062,5732,4232,2702,089
Machinery
-2,2852,1491,9401,8031,662
Construction In Progress
-1,8901,7221,345980.5767.7
Leasehold Improvements
-174.4154.5133.9114.3113.9
SEC Filings: 10-K · 10-Q